Axsome Therapeutics beats Q1 expectations, shares rise

Published 05/05/2025, 12:26
Axsome Therapeutics beats Q1 expectations, shares rise

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected first quarter results on Monday, driven by strong sales growth of its key products AUVELITY and SUNOSI.

The biopharmaceutical company’s shares rose 1.60% in premarket trading following the earnings release.

Axsome posted a Q1 loss of $1.22 per share, narrower than analysts’ estimates of a $1.30 per share loss. Revenue surged 62% YoY to $121.5 million, roughly in line with expectations of $121.58 million.

AUVELITY net product sales jumped 80% YoY to $96.2 million, while SUNOSI net product revenue grew 17% to $25.2 million. Total (EPA:TTEF) prescriptions for AUVELITY increased 76% compared to the same period last year.

"The first quarter was strong and eventful, with the approval of SYMBRAVO for the acute treatment of migraine, continued growth of AUVELITY and SUNOSI, and significant advancements across our broad late-stage neuroscience pipeline," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.

The company maintained its guidance that current cash is sufficient to fund operations into cash flow positivity. Axsome ended the quarter with $300.9 million in cash and cash equivalents.

Looking ahead, Axsome plans to launch SYMBRAVO commercially in June 2025. The company also expects to submit regulatory filings for several pipeline candidates this year, including AXS-05 for Alzheimer’s disease agitation and AXS-12 for narcolepsy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.